

Product datasheet for **CF804155**

TACC2 Mouse Monoclonal Antibody [Clone ID: OTI7F12]

Product data:

Product Type:	Primary Antibodies
Clone Name:	OTI7F12
Applications:	WB
Recommended Dilution:	WB 1:200
Reactivity:	Human
Host:	Mouse
Isotype:	IgG2a
Clonality:	Monoclonal
Immunogen:	Human recombinant protein fragment corresponding to amino acids 727-1026 of human TACC2 (NP_008928) produced in E.coli.
Formulation:	Lyophilized powder (original buffer 1X PBS, pH 7.3, 8% trehalose)
Reconstitution Method:	For reconstitution, we recommend adding 100uL distilled water to a final antibody concentration of about 1 mg/mL. To use this carrier-free antibody for conjugation experiment, we strongly recommend performing another round of desalting process. (OriGene recommends Zeba Spin Desalting Columns, 7KMWCO from Thermo Scientific)
Purification:	Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G)
Conjugation:	Unconjugated
Storage:	Store at -20°C as received.
Stability:	Stable for 12 months from date of receipt.
Gene Name:	transforming acidic coiled-coil containing protein 2
Database Link:	NP_008928 Entrez Gene 10579 Human O95359




[View online »](#)

Background:

Transforming acidic coiled-coil proteins are a conserved family of centrosome- and microtubule-interacting proteins that are implicated in cancer. This gene encodes a protein that concentrates at centrosomes throughout the cell cycle. This gene lies within a chromosomal region associated with tumorigenesis. Expression of this gene is induced by erythropoietin and is thought to affect the progression of breast tumors. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

Synonyms:

AZU-1; ECTACC

Product images:

HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY TACC2 ([RC215999], Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-TACC2.